Results 41 to 50 of about 11,382 (203)
Drug Design, Development and Therapy, 2020 Amanda L Blackmon,1 Lauren Pinter-Brown1,2 1Division of Hematology/Oncology, Department of Medicine, University of California, Irvine, Irvine, CA, USA; 2Chao Family Comprehensive Cancer Center, University of California, Irvine, Irvine, CA ...
Blackmon AL, Pinter-Brown L
doaj
MicroRNA expression profiling and DNA methylation signature for deregulated microRNA in cutaneous T-cell lymphoma [PDF]
, 2017 MicroRNAs usually regulate gene expression negatively, and aberrant expression has been involved in the development of several types of cancers. Microarray profiling of microRNA expression was performed to define a microRNA signature in a series of ...
Climent, Fina +14 more
core +1 more source
Dupilumab Beyond the Airway: Decreased Morbidity in a Real‐World Analysis
International Forum of Allergy &Rhinology, EarlyView.ABSTRACT Background Post hoc analyses of clinical trials have characterized dupilumab's adverse effects, yet the real‐world impact in chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma is not well described. This study aims to characterize the risks of lymphoma, cardiovascular events, eosinophilia, joint pain, inflammatory arthritis, and ...
Emma J. Anisman +9 more
wiley +1 more source
Case Reports in Dermatology, 2018 Papuloerythroderma of Ofuji (PEO) is an erythroderma-like eruption with flat-topped papules that spare the skin folds (a “deck-chair sign” finding). Many infections, medications, and systemic diseases have been associated with PEO, including cutaneous T ...
Anthony M. Maher +3 more
doaj +1 more source
Dupilumab and Systemic Hematologic Malignancies: Case Series and Literature Review
JEADV Clinical Practice, EarlyView.ABSTRACT Background Atopic dermatitis (AD) is a chronic inflammatory skin disease affecting 15%–20% of children and 3%–10% of adults. An increased risk of systemic lymphomas – but not leukemias – has been reported in patients with AD. Dupilumab, a monoclonal IgG4 antibody targeting IL‐4 and IL‐13 signaling, is approved for moderate‐to‐severe AD and is ...
Nello Tommasino +3 more
wiley +1 more source
OncoImmunology, 2018 CTCL follows different courses depending on the clinical stage at the time of diagnosis. Patients with early stage Mycosis Fungoides (MF) variant of CTCL may experience an indolent course over decades, whereas patients with advanced MF and Sézary ...
Philippe Lefrançois +13 more
doaj +1 more source
The Skin Microbiome in Cutaneous T-Cell Lymphomas (CTCL)—A Narrative Review
Pathogens, 2022 In recent years, numerous studies have shown a significant role of the skin microbiome in the development and exacerbation of skin diseases. Cutaneous T-cell lymphomas (CTCL) are a group of malignancies primary involving skin, with unclear pathogenesis ...
Magdalena Łyko, Alina Jankowska-Konsur
doaj +1 more source
DMF: a promising therapeutic option in CTCL [PDF]
Blood, 2016 In this issue of Blood , Nicolay et al present their exciting findings that show that dimethyl fumarate (DMF) specifically inhibits NF-κB activity in cutaneous T-cell lymphoma (CTCL) cells, thus inducing their apoptosis, while having minimal effect on healthy T cells (see figure). Their study suggests that DMF may represent a new promising therapeutic
openaire +2 more sources
Categorization of Reasons for Hospitalizations in Patients With Cutaneous T‐Cell Lymphoma
JEADV Clinical Practice, EarlyView.ABSTRACT Background Cutaneous T‐cell lymphomas (CTCL) can significantly impact patients' quality of life as well as impose a substantial healthcare burden due to their complex management and risk of hospitalization. Objectives This study aimed to identify factors associated with hospital admissions among patients with CTCL and to characterize the ...
Geetha Gowda +6 more
wiley +1 more source
Simultaneous colonic T-cell lymphoma and graft-versus-host disease: A rare diagnosis
Human Pathology: Case Reports, 2021 Cutaneous T-cell lymphoma (CTCL) presenting as mycosis fungoides is typically localized to the skin and occasional draining lymph nodes. We present a 46-year-old man with refractory CTCL status-post allogeneic stem cell transplant who was biopsied for ...
Savanah D. Gisriel +6 more
doaj +1 more source